Opioid withdrawal is rarely fatal itself, but relapse after withdrawal carries extreme overdose risk. Tolerance drops within days of stopping — a previously "normal" dose can cause fatal overdose after even brief abstinence. If you or someone you know is stopping opioids, please contact a doctor, call SAMHSA at 1-800-662-4357, or go to an emergency room. Naloxone (Narcan) should be available. This is a medical situation.
Opioid withdrawal symptoms: anxiety, agitation, muscle cramps, sweating, goosebumps, runny nose, nausea, vomiting, diarrhea, and rapid heart rate. Short-acting opioids (heroin, oxycodone): onset 8–24 hours, peak 36–72 hours, resolve 5–7 days. Long-acting (methadone): onset 36–48 hours, peaks later, lasts 2–3 weeks. Withdrawal is not typically fatal — the deadly danger is relapse after abstinence, when tolerance has dropped and a previous dose causes overdose. Medication-assisted treatment (buprenorphine, methadone, naltrexone) reduces overdose mortality by 50%+ and is the evidence-based standard of care.
Intense restlessness, inability to get comfortable, psychological panic. Often the first and most distressing symptom.
Severe, flu-like muscle pain throughout the body. "Bone-deep" aching is a classic descriptor. Peak intensity at 36–72 hrs.
Profuse sweating alternating with chills and goosebumps ("cold turkey" — the appearance of goose skin gave the term its name).
Lacrimation (tearing eyes) and rhinorrhea (runny nose) are autonomic symptoms of opioid withdrawal — controlled by the sympathetic nervous system.
Can be severe and lead to dangerous dehydration. Anti-nausea medications help significantly. IV fluids may be needed for severe cases.
Severe abdominal cramping and diarrhea, sometimes lasting days. Opioids slow GI motility — removal causes rebound hypermotility.
Severe sleep disruption, often the most persistent symptom. Can last weeks after acute withdrawal resolves.
Uncontrollable excessive yawning is a specific autonomic sign of opioid withdrawal, appearing early (6–12 hours into withdrawal).
Opioids constrict pupils (miosis). Withdrawal causes the opposite — dilated pupils (mydriasis) are a clinical sign of active withdrawal.
Tachycardia and hypertension reflect sympathetic nervous system activation. Usually manageable; rarely requires emergency intervention on its own.
Short-acting opioids (heroin, oxycodone, hydrocodone, morphine): first symptoms appear 8–24 hours after last dose. Long-acting opioids (methadone): slower onset at 36–48 hours. Yawning, runny nose, anxiety, and restlessness are typically first to appear.
The most intense phase. Muscle cramps, vomiting, diarrhea, sweating, and extreme agitation reach maximum intensity. This is the window of greatest relapse risk — the discomfort is severe enough that most people relapse without medical support or MAT. Dehydration risk is highest here.
Physical symptoms begin subsiding. Muscle aches ease. GI symptoms improve. Energy starts returning. Insomnia and anxiety persist longest. Short-acting opioid withdrawal largely resolves by day 7; methadone withdrawal can extend to 2–3 weeks.
After acute withdrawal resolves, many people experience PAWS: persistent anxiety, depression, sleep difficulty, cognitive fog, and drug cravings that can last months to over a year. PAWS is the primary driver of long-term relapse risk and is a key reason MAT — which manages PAWS symptoms pharmacologically — dramatically improves recovery outcomes.
COWS (Clinical Opiate Withdrawal Scale) is used by clinicians to assess withdrawal severity and time buprenorphine induction. Starting buprenorphine too early can precipitate severe precipitated withdrawal.
Buprenorphine induction typically begins when COWS score reaches 8–12 (early moderate withdrawal). A COWS score of 0–7 suggests too early for induction.
Opioid tolerance — the brain's adaptation to regular opioid exposure — drops rapidly during withdrawal. Within 3–5 days of stopping, someone's tolerance may have fallen to a fraction of what it was. A dose that was "normal" before withdrawal can now cause fatal respiratory depression.
This is the primary reason the post-withdrawal period carries the highest overdose mortality risk of any phase of opioid use. It explains the pattern seen in overdose statistics: people who have recently left incarceration, completed inpatient detox, or been briefly hospitalized are massively overrepresented in overdose deaths, because their tolerance dropped during the gap and they returned to prior doses.
Medication-assisted treatment — particularly buprenorphine and methadone, which maintain opioid receptor engagement at a managed level — is the single most effective intervention for preventing this outcome. Studies show MAT reduces opioid overdose mortality by 50% or more.
Partial opioid agonist. Reduces cravings and withdrawal without producing a strong high. Can be prescribed by office-based physicians. First-line treatment for OUD.
Long-acting full agonist. Highly effective for severe OUD. Dispensed through licensed clinics. Eliminates withdrawal while blocking illicit opioid effects.
Opioid antagonist — blocks opioid effects entirely. Monthly injection. Requires full detox first (no active opioids). Effective for motivated patients with support systems.
Anxiety, agitation, muscle cramps, sweating, goosebumps, runny nose, tearing eyes, yawning, nausea, vomiting, diarrhea, abdominal cramps, insomnia, elevated heart rate, and dilated pupils. Begin 8–24 hours after last dose (short-acting) or 36–48 hours (long-acting).
Short-acting: peaks at 36–72 hours, largely resolves in 5–7 days. Long-acting (methadone): peaks later, lasts 2–3 weeks. PAWS (anxiety, depression, cravings, insomnia) can persist for months to over a year.
The withdrawal itself is rarely fatal (unlike alcohol). The danger is dehydration from vomiting/diarrhea, and critically — relapse overdose risk. Tolerance drops rapidly during withdrawal; returning to a prior dose can be fatal. Medical supervision and naloxone availability are important.
Clinical Opiate Withdrawal Scale — an 11-item clinical assessment used to measure withdrawal severity and guide buprenorphine induction timing. Scores: 5–12 mild, 13–24 moderate, 25–36 moderately severe, 37+ severe.
Medication-assisted treatment uses buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) combined with counseling to treat opioid use disorder. MAT reduces overdose mortality by 50%+ and is the evidence-based standard of care per SAMHSA and ASAM.
Relapse after abstinence. Tolerance drops within days of stopping — a prior "normal" dose can cause fatal overdose after even brief abstinence. The post-detox period is the highest-risk window for overdose death.
Forge tracks your streak, logs cravings, and marks every milestone as your body heals. Free to download.
Download Forge Free →